Seattle-based Juno Therapeutics (Nasdaq: JUNO) has more than doubled the amount of cash it has, giving it a deeper pool of capital for its cancer research.
The company, which is at the forefront of immunotherapy cancer treatments, ended 2015 with $1.22 billion in cash. That’s a big jump from the $474 million in cash Juno had at the end of the previous year, according to data released Monday in the company’s annual earnings report.
